• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨桥蛋白表达对 CC531 大鼠结直肠癌细胞在大鼠肝脏转移生长的影响。

Influence of osteopontin expression on the metastatic growth of CC531 rat colorectal carcinoma cells in rat liver.

机构信息

Chemotherapy and Toxicology Unit, German Cancer Research Center, Heidelberg.

出版信息

Cancer Gene Ther. 2011 Nov;18(11):795-805. doi: 10.1038/cgt.2011.48. Epub 2011 Aug 19.

DOI:10.1038/cgt.2011.48
PMID:21852811
Abstract

Development of hepatic metastasis is responsible for most of colorectal cancer-related deaths. Osteopontin (OPN) is a small integrin-binding N-linked glycoprotein, which plays a crucial role in the formation of hepatic metastasis. This study aimed to suppress Opn expression by an antisense-oligonucleotide (ASO(Opn)) to decrease liver metastasis in vivo. The effect of ASO(Opn) was investigated in vitro in CC531(lacZ) colorectal cancer cells in comparison to sense (SO) or nonsense (NSO) oligomers, by determining mRNA and protein expression levels, as well as cell survival. For in vivo treatment, CC531(lacZ) cells were intraportally inoculated into rats to compare the effects of ASO, SO and NSO oligomers, following prolonged subcutaneous administration by osmotic mini-pumps. The resulting CC531(lacZ) tumor cell load in the liver was measured by a β-galactosidase assay. Proliferation of CC531(lacZ) cells in vitro was significantly decreased after ASO(Opn) and SO treatment (P<0.001). Liver metastasis development was reduced as long as ASO(Opn) was administered, but this effect was rapidly blunted following the end of the ASO(Opn) administration. In contrast, administration of the SO resulted in a tumor load reduction, which surprisingly surpassed the ASO(Opn) effect in vivo in terms of a long-lasting metastasis suppression, which was accompanied with increased survival of the animals. Administration of the ASO(Opn) in rats was effective in decreasing their liver metastasis. The short-lived effect might be extended by modifications suited to increase the ASOs' half-life. In addition, there was a superior anti-metastatic effect caused by the SO, which has not been reported previously.

摘要

肝转移的发展是导致大多数结直肠癌相关死亡的原因。骨桥蛋白(OPN)是一种小的整合素结合的 N 连接糖蛋白,在肝转移的形成中起着关键作用。本研究旨在通过反义寡核苷酸(ASO(Opn))抑制 Opn 表达,从而减少体内肝转移。通过确定 mRNA 和蛋白表达水平以及细胞存活,在 CC531(lacZ)结直肠癌细胞中体外研究 ASO(Opn)与正义(SO)或无义(NSO)寡聚物的作用,与 SO 或 NSO 寡聚物相比,反义寡核苷酸(ASO(Opn))处理后,CC531(lacZ)细胞的 mRNA 和蛋白表达水平降低,细胞存活率降低。在体内治疗中,通过渗透微型泵进行皮下延长给药,将 CC531(lacZ)细胞门静脉内接种到大鼠体内,比较 ASO、SO 和 NSO 寡聚物的作用。通过β-半乳糖苷酶测定法测量肝内 CC531(lacZ)肿瘤细胞负荷。ASO(Opn)和 SO 处理后,CC531(lacZ)细胞体外增殖明显减少(P<0.001)。只要给予 ASO(Opn),肝转移的发展就会减少,但随着 ASO(Opn)给药的结束,这种效果很快就减弱了。相反,给予 SO 可导致肿瘤负荷减少,令人惊讶的是,在体内,这种效果超过了 ASO(Opn)的长期抑制转移作用,同时动物的存活率也提高了。ASO(Opn)在大鼠体内给药有效降低了其肝转移。这种短暂的效果可以通过适合增加 ASO 半衰期的修饰来延长。此外,SO 具有优越的抗转移作用,这是以前没有报道过的。

相似文献

1
Influence of osteopontin expression on the metastatic growth of CC531 rat colorectal carcinoma cells in rat liver.骨桥蛋白表达对 CC531 大鼠结直肠癌细胞在大鼠肝脏转移生长的影响。
Cancer Gene Ther. 2011 Nov;18(11):795-805. doi: 10.1038/cgt.2011.48. Epub 2011 Aug 19.
2
Regulation of osteopontin and related proteins in rat CC531 colorectal cancer cells.调控大鼠 CC531 结肠癌细胞中骨桥蛋白及相关蛋白的表达
Int J Oncol. 2010 Aug;37(2):249-56.
3
Down-regulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via a mechanism involving MMP-2 and uPA.骨桥蛋白下调通过涉及 MMP-2 和 uPA 的机制抑制肝癌细胞转移。
Oncol Rep. 2011 Mar;25(3):803-8. doi: 10.3892/or.2010.1116. Epub 2010 Dec 21.
4
Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells.骨桥蛋白和骨唾液酸蛋白II的下调与MDA-MB-231人乳腺癌细胞集落形成减少和转移形成减少有关。
Cancer Gene Ther. 2004 Feb;11(2):109-20. doi: 10.1038/sj.cgt.7700659.
5
Interferon-induced transmembrane 3 binds osteopontin in vitro: expressed in vivo IFITM3 reduced OPN expression.干扰素诱导跨膜蛋白 3 体外结合骨桥蛋白:体内表达 IFITM3 降低 OPN 表达。
Oncogene. 2010 Feb 4;29(5):752-62. doi: 10.1038/onc.2009.379. Epub 2009 Nov 9.
6
Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis.小干扰RNA介导的骨桥蛋白沉默可抑制CT26小鼠结肠腺癌的体内外转移。
Carcinogenesis. 2005 Apr;26(4):741-51. doi: 10.1093/carcin/bgi027. Epub 2005 Jan 20.
7
EF1A1-actin interactions alter mRNA stability to determine differential osteopontin expression in HepG2 and Hep3B cells.EF1A1与肌动蛋白的相互作用改变mRNA稳定性,以确定HepG2和Hep3B细胞中骨桥蛋白的差异表达。
Exp Cell Res. 2009 Jan 15;315(2):304-12. doi: 10.1016/j.yexcr.2008.10.042. Epub 2008 Nov 7.
8
Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells.整合素连接激酶调节骨桥蛋白依赖性基质金属蛋白酶-2和尿激酶型纤溶酶原激活剂的表达,以传递小鼠乳腺上皮癌细胞的转移功能。
Carcinogenesis. 2006 Jun;27(6):1134-45. doi: 10.1093/carcin/bgi352. Epub 2006 Feb 12.
9
[Expression of osteopontin mRNA and its protein in colorectal cancer and liver metastatic tissues].骨桥蛋白mRNA及其蛋白在结直肠癌和肝转移组织中的表达
Zhonghua Yi Xue Za Zhi. 2002 Jul 25;82(14):970-3.
10
Suppression of colorectal cancer liver metastasis and extension of survival by expression of apolipoprotein(a) kringles.载脂蛋白(a)kringle的表达对结直肠癌肝转移的抑制及生存期的延长作用
Cancer Res. 2004 Oct 1;64(19):7092-8. doi: 10.1158/0008-5472.CAN-04-0364.

引用本文的文献

1
Inhibition of cell proliferation, migration and colony formation of LS174T Cells by carbonic anhydrase inhibitor.碳酸酐酶抑制剂对LS174T细胞增殖、迁移及集落形成的抑制作用
Afr Health Sci. 2018 Dec;18(4):1303-1310. doi: 10.4314/ahs.v18i4.51.
2
Investigation of Metastasis-Related Genes: A Rat Model Mimicking Liver Metastasis of Colorectal Carcinoma.转移相关基因的研究:一种模拟结直肠癌肝转移的大鼠模型
Front Oncol. 2017 Jul 18;7:152. doi: 10.3389/fonc.2017.00152. eCollection 2017.
3
Prognostic value of tumor progression-related gene expression in colorectal cancer patients.
结直肠癌患者肿瘤进展相关基因表达的预后价值。
J Cancer Res Clin Oncol. 2012 Oct;138(10):1631-40. doi: 10.1007/s00432-012-1238-7. Epub 2012 May 22.